Jaguar Health JAGX
NASDAQ JAGX
$0.87 -0.01 (-0.69%)
At close: Aug 21, 2026 · 4:00 PM EDT

Jaguar Health (JAGX) Asset Writedowns and Impairment (2019)

Jaguar Health (JAGX) posted quarterly Asset Writedowns and Impairment of $4.0 million for Q2 2019.

Jaguar Health (JAGX) Asset Writedowns and Impairment (2019) Analysis & Trends

Jaguar Health (JAGX) has reported Asset Writedowns and Impairment for 1 consecutive years, with $4.0 million the latest figure, recorded in Q2 2019.

  • In Q2 2019, Asset Writedowns and Impairment changed N/A year-over-year to $4.0 million; the TTM figure through Jun 2020 stood at $4.0 million (changed 0.0% YoY), while the FY2025 annual figure was $800000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment was little changed at $4.0 million in Q2 2019 per JAGX's latest filing.
  • Across five years, Asset Writedowns and Impairment topped out at $4.0 million in Q2 2019 and bottomed at $4.0 million in Q2 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Jaguar Health 447,549.24 -9.62 Mn 19.11 Mn

Historic Data

Download Data
DateValue
Jun 30, 2019 4.00 Mn
Jun 30, 2019 4.00 Mn